Virologic Response Following Combined Ledipasvir and Sofosbuvir Administration in Patients With HCV Genotype 1 and HIV Co-infection

Anu Osinusi, MD, MPH; Kerry Townsend, BA; Anita Kohli, MD, MS; Amy Nelson, RN; Cassie Seamon, RN; Eric G. Meissner, MD, PhD; Dimitra Bon, MS; Rachel Silk, RN; Chloe Gross, RN; Angie Price, NP; Mohammad Sajadi, MD; Sreetha Sidharthan, BS; Zayani Sims, BS; Eva Herrmann, PhD; John Hogan, MD; Gebeeyehu Teferi, MD; Rohit Talwani, MD; Michael Proschan, PhD; Veronica Jenkins, MD; David E. Kleiner, MD, PhD; Brad J. Wood, MD; G. Mani Subramanian, MD, PhD; Phillip S. Pang, MD, PhD; John G. Mchutchison, MD; Michael A. Polis, MD, MPH; Anthony S. Fauci, MD; Henry Masur, MD; Shyam Kottilil, MD, PhD

IMPORTANCE There is an unmet need for interferon- and ribavirin-free treatment for chronic hepatitis C virus (HCV) infection in patients co-infected with human immunodeficiency virus (HIV).

OBJECTIVE To evaluate the rates of sustained virologic response (SVR) and adverse events in previously untreated patients with HCV genotype 1 and HIV co-infection following a 12-week treatment of the fixed-dose combination of ledipasvir and sofosbuvir.

DESIGN, SETTING, AND PARTICIPANTS Open-label, single-center, phase 2b pilot study of previously untreated, noncirrhotic patients with HCV genotype 1 and HIV co-infection conducted at the Clinical Research Center of the National Institutes of Health, Bethesda, Maryland, from June 2013 to September 2014. Patients included those receiving antiretroviral therapy with HIV RNA values of 50 copies/mL or fewer and a CD4 T-lymphocyte count of 100 cells/mL or greater or patients with untreated HIV infection with a CD4 T-lymphocyte count of 500 cells/mL or greater. Serial measurements of safety parameters, virologic and host immune correlates, and adherence were performed.

INTERVENTIONS Fifty patients with HCV genotype 1 never before treated for HCV were prescribed a fixed-dose combination of ledipasvir (90 mg) and sofosbuvir (400 mg) once daily for 12 weeks.

MAIN OUTCOMES AND MEASURES The primary study outcome was the proportion of patients with sustained viral response (plasma HCV RNA level <12 IU/mL) 12 weeks after end of treatment.

RESULTS Forty-nine of 50 participants (98% [95% CI, 89% to 100%]) achieved SVR 12 weeks after end of treatment, whereas 1 patient experienced relapse at week 4 following treatment. In the patient with relapse, deep sequencing revealed a resistance associated mutation in the NS5A region conferring resistance to NS5A inhibitors, such as ledipasvir. The most common adverse events were nasal congestion (16% of patients) and myalgia (14%). There were no discontinuations or serious adverse events attributable to study drug.

CONCLUSIONS AND RELEVANCE In this open-label, uncontrolled, pilot study enrolling patients co-infected with HCV genotype 1 and HIV, administration of an oral combination of ledipasvir and sofosbuvir for 12 weeks was associated with high rates of SVR after treatment completion. Larger studies that also include patients with cirrhosis and lower CD4 T-cell counts are required to understand if the results of this study generalize to all patients co-infected with HCV and HIV.

TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT01878799

JAMA. doi:10.1001/jama.2015.1373
Published online February 23, 2015.

Author Affiliations: Author affiliations are listed at the end of this article.

Corresponding Author: Shyam Kottilil, MD, PhD, Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, 725 W Lombard St, Room S222, Baltimore, MD 21201 (skottilil@ihv.umaryland.edu).
Approximately 185 million people are infected with chronic hepatitis C (HCV) infection worldwide, and about 5 million are co-infected with human immunodeficiency virus (HIV). In the United States, co-infection occurs in approximately one-third of all patients with HIV-1 infection, with incidence rates as high as 75% to 90% among patients with reported history of intravenous drug use, and is associated with higher rates of end-stage liver disease, liver cancer, and mortality.2,3

Prior to 2013, treatment of HCV genotype-1 infection in individuals with HIV co-infection required 24 to 48 weeks of pegylated interferon, ribavirin, and a protease inhibitor (either boceprevir or telaprevir). Although this regimen was associated with improved rates of sustained virologic response (SVR) when compared with those observed with pegylated interferon and ribavirin alone, widespread use was limited because of high rates of adverse events, discontinuation rates, and complex drug-drug interactions.4,8,9

In 2013, 2 new directly acting antiviral agents—sofosbuvir, an HCV NS5B polymerase inhibitor, and simeprevir, an NS5A protease inhibitor—were licensed for treatment of HCV.10,11 Although sofosbuvir and ribavirin for 24 weeks was associated with high rates of SVR in HIV-negative and HIV-positive patients with HCV genotype 1,12,13 modest rates of hemoglobin decline were attributable to concomitant use of ribavirin. Recent studies evaluating the combination of ledipasvir, an HCV NS5A inhibitor, along with sofosbuvir, in a fixed-dose combination with or without ribavirin for 8 to 24 weeks, have demonstrated SVR rates of 91% to 100% in patients monoinfected with HCV genotype 1 who either have or have not previously received HCV treatment.5,7,14,15 In this study, we evaluated the rates of SVR following a 12-week treatment regimen of a fixed-dose combination of ledipasvir and sofosbuvir in patients co-infected with HCV genotype 1 and HIV who were not previously treated for HCV.

Methods

Participants

Participants were enrolled in a single-center, open-label, uncontrolled, nonrandomized phase 2b trial conducted at the Clinical Research Center of the National Institutes of Health (NIH), Bethesda, Maryland, from June 2013 to September 2014. Patients were recruited from existing HCV clinics in the District of Columbia as previously described.13 Patients were contacted for screening based on the order of initial communication with the study team and for start of study drugs based on completion of eligibility requirements. The study protocol is available in Supplement 1.

Eligible participants were at least 18 years old, had not received prior HCV treatment, and were co-infected with HCV genotype 1 and HIV. Participants could either not be receiving antiretroviral therapy with a CD4 T-lymphocyte count of 500 cells/mm³ or greater regardless of HIV viral load, a stable CD4 count with HIV viral load less than 500 copies/mL, or could be receiving a protocol-approved antiretroviral regimen with HIV RNA values of 50 copies/mL or fewer with a CD4 T-lymphocyte count of 100 cells/μL or greater. Participants receiving antiretroviral drugs were required to have been receiving a stable treatment regimen for at least 8 weeks prior to starting study drug. Acceptable antiretroviral drugs were emtricitabine plus tenofovir and/or efavirenz, raltegravir, or rilpivirine.

Participants with cirrhosis, who may be less responsive to HCV treatment, were excluded from this investigational study. The presence or absence of cirrhosis was determined by liver biopsy within the previous 3 years of enrollment or by a combination of FibroSURE (Laboratory Corporation of America) score less than 0.48 and aspartate aminotransferase/platelet ratio index less than 1. A FibroSURE score less than 0.48 corresponds with a fibrosis stage from 0 to 2.

Race and ethnicity were self-reported. All eligible participants were required to have a primary medical provider and, if opioid-dependent, needed to be participating in supervised treatment. Full eligibility criteria are included in eAppendix 1 in Supplement 2.

Study Oversight

The study was approved by the National Institute of Allergy and Infectious Diseases (NIAIID) institutional review board and was conducted in compliance with the Good Clinical Practice guidelines, the Declaration of Helsinki, and regulatory requirements. Written or oral informed consent approved by the NIAID institutional review board was obtained from all participants. The Regulatory Compliance and Human Participants Protection Branch of NIAID served as the study sponsor and medical monitor. Data collection, review and analysis, and writing were performed by NIH and Institute of Human Virology investigators.

Study Design

Participants from outpatient community clinics were prescribed a combination tablet containing ledipasvir (90 mg) and sofosbuvir (400 mg), administered orally for 12 weeks. Patients received instructions for proper administration of study drug. Criteria for stopping study medications were based on specific safety or virologic measures. Participants would be discontinued from therapy if they did not achieve a greater than 2 log₁₀ decrease in HCV RNA values (unless a >2 log₁₀ decrease would be below the lower limit of quantification [LLOQ] at their week 4 visit or if their serum RNA level was greater than or equal to the LLOQ at their week 8 visit [eAppendix 2 in Supplement 2]). Participants who did not achieve SVR 12 weeks after treatment completion (SVR₁₂) were offered the option of additional treatment with the current standard of care. In addition to their screening visit, patients were reminded to return to the NIH for outpatient visits at days 0, 1, 3, 5, 7, and 10 and weeks 2, 3, 4, 8, 12, 14, 16, 20, and 24, which corresponds to an SVR₁₂ visit.

Outcome Measures

Plasma HCV RNA levels were measured using the real-time HCV assay (Abbott), with an LLOQ of 12 IU/mL. The assay was used to measure HCV RNA levels in all participants at all time points. Serum HCV RNA levels were also measured using the COBAS TaqMan HCV RNA assay version 2.0 (Roche), with an LLOQ of

Downloaded From: http://jama.jamanetwork.com/ by Jules Levin on 02/24/2015
43 IU/mL at screening, week 4, week 8, end of treatment, 4 weeks after treatment, and 12 weeks after treatment. Plasma HIV RNA levels were measured at all points using reverse transcription polymerase chain reaction (real-time HIV assay), with an LLOQ of 40 copies/mL.

Hepatitis C viral relapse was defined as an HCV RNA level higher than the LLOQ at any posttreatment point after having an HCV RNA level lower than the LLOQ at the end of treatment. Hepatitis C viral breakthrough was defined as an HCV RNA level at the LLOQ or higher during treatment after having previously had an HCV RNA level lower than the LLOQ while taking study drugs, confirmed with 2 consecutive values. Renal function was assessed using both creatinine levels and estimated glomerular filtration rate (eGFR, calculated using the CKD-EPI equation).16

Safety and Adherence
Adverse events and clinical laboratory results were recorded throughout the study. Adverse events were graded from 1 (mild) to 4 (severe) according to the NIAID Division of AIDS toxicity table (version 1.0).17 Patient adherence was determined by pill counts at weeks 1, 4, 8, and end of treatment. Patients were determined to be fully adherent to the regimen if they missed no doses over the course of treatment.

Viral Kinetics
During the first 28 days of treatment, HCV RNA levels were measured at day 0, 1, 3, 5, 7, 10, 14, 21, and 28 in all patients. In 20 patients (10 not receiving antiretroviral treatment and 10 receiving antiretroviral treatment), HCV RNA levels were also obtained at 0, 1, 2, 4, 8, 12, 24, and 36 hours after administration of first dose of study.

**IL28B and IFNL4 Genotyping**
IL28B and IFNL4 single-nucleotide polymorphisms have previously been described as determinants of SVR.18,19 IL28B and IFNL4 genotype was determined on DNA specimens using 5' nuclease assay with IL28B and IFNL4 allele-specific TaqMan probes (ABI TaqMan allelic discrimination kit) and the ABI7500 Real-Time PCR system (Applied Biosystems). Genotyping of variants at the rs12979860 (referred to as IL28B genotype) and rs368234815 (IFNL4) loci was performed as previously described.16

Liver Biopsy
An optional additional liver biopsy was offered after treatment completion to participants who had an initial liver biopsy performed at the NIH Clinical Center. Assessments were performed by a single pathologist and staged according to the Knodell Histological Activity Index.20

Clinical End Points
The primary end point was sustained virologic response (HCV RNA level <12 IU/mL by real-time HIV assay) at 12 weeks after treatment completion (SVR12) among all patients enrolled in the study. Safety end points included frequency and severity of adverse events, discontinuations attributable to adverse events, and safety laboratory changes.

Secondary end points that have been completed and included here are the proportion of participants with unquantifiable HCV viral load at specified points during and after treatment, discontinuations attributable to adverse events, safety laboratory changes, and evaluation of HCV resistance mutations in the patient who experienced relapse. Data through SVR12 are included here.

**Modeling Viral Kinetics**
Viral kinetic modeling with a multiscale model was performed for all participants as previously described.21,22 A detailed version of the methodology is described in eAppendix 3 in Supplement 2.

**Deep Sequencing**
Deep sequencing of the HCV NS5A and NS5B regions was performed only for the patient who experienced relapse, from samples collected at baseline and at the time of virologic failure, using DDL (DDL Diagnostics Laboratory). The NS3, NS5A, and NS5B were amplified by RT-PCR using HCV genotype-specific primers. The PCR products were sequenced by Illumina MiSeq technology as described elsewhere.23 Deep sequencing that covers 5000 reads was performed for each sample.

**Statistical Analysis**
The primary virologic response and safety analyses were based on an intention-to-treat population (all patients who received at least 1 dose of study medication). In terms of safety, a sample size of 50 was calculated as sufficient to have a 96% chance of observing at least 1 adverse event having a probability of 10% or greater. With 50 participants, the study would be able to estimate the proportion of patients with suppression to below the limit of detection to within plus or minus 0.11, based on a 95% confidence interval.

Baseline demographics were compared using the Wilcoxon rank-sum test for continuous outcomes and χ2 tests for binary outcomes. Estimated decline in HCV viral load at different times was compared using a Wilcoxon rank-sum test. Analyses were performed using BIAS, PRISM 6.0 (GraphPad), SAS (SAS Institute Inc), STAT-CRUNCH, and S-Plus 8.0.

**Results**

**Baseline Characteristics**
Sixty-three potential participants were screened and 50 were enrolled (eFigure 1 in Supplement 2). Six participants screened and declined to participate, and 7 participants did not meet inclusion criteria (see eTable 1 in Supplement 2 for reasons for exclusion). Of the 50 enrolled, 37 were receiving antiretroviral treatment and 13 were not receiving antiretroviral treatment.

The demographic and baseline clinical characteristics are shown in Table 1. Median baseline CD4 count was 576 (95% CI, 453-657) cells/mm3 for patients receiving antiretroviral treatment and 687 (95% CI, 518-960) cells/mm3 for patients not receiving antiretroviral treatment. Participants...
were predominantly African American (84%), men (74%), *IL28B* non-CC genotype (84%), with genotype 1a infection (74%). Thirteen of 50 patients (26%) had stage 3 liver disease.

### Virologic Response During and After Treatment

All 50 participants achieved virologic suppression lower than the LLOQ by week 4 of therapy (Table 2; eTable 2 in Supplement 2). All 13 participants not receiving antiretroviral treatment achieved SVR12 (100%; 95% CI, 75%-100%). Of the 37 participants receiving antiretroviral treatment, 36 (97%; 95% CI, 89%-100%) achieved SVR12.

### Changes in Liver Function

Levels of alanine aminotransferase and aspartate aminotransferase normalized rapidly with treatment (eFigure 2 in Supplement 2). A comparison of pretreatment and post-treatment paired liver biopsies showed Knodell Histological Activity Index inflammation improved by a mean of 2.2 (from 8.07 to 5.86) with treatment (P = .01) (eFigure 3 in Supplement 2).

One patient did not achieve SVR12 and experienced relapse by week 4 after treatment completion. This was a 63-year-old African American woman, *IL28B* non-CC genotype, with genotype 1b infection, a baseline HCV viral load of 5,338,580 IU/mL by real-time HIV assay, and stage 1 liver disease. She was receiving tenofovir plus emtricitabine and rilpivirine for HIV infection with virologic suppression. She achieved virologic suppression lower than the LLOQ by week 4, which was maintained through 12 weeks. At week 4 after treatment completion, HCV viral load was 64,749 IU/mL by real-time HIV assay. This patient has been lost to follow-up.

### Viral Resistance Testing

Deep sequencing was carried out for the 1 participant who experienced relapse. The only mutation was seen in the NS5A region. The participant had 58% of Y93H mutation at baseline,
which was enriched to 89% at day 3 and to greater than 99% at relapse. This mutation confers resistance to NS5A inhibitors, such as ledipasvir in vitro.

**HCV Viral Kinetic Response**

Viral kinetic modeling showed a rapid, sustained decline in HCV RNA in both groups (Figure). This multistage model was fitted in each participant shown in eFigure 4 in Supplement 2. Median overall treatment effect (ε) observed in participants receiving and not receiving antiretroviral treatment was similar (treated, 99.98%; not treated, 99.98%; \( P = .78 \)). Clearance rate (c) of free virions (9.05 vs 10.3, \( P = .68 \)) and loss of infected hepatocytes (δ) (0.13 vs 0.17, \( P = .25 \)) were not significantly different between patients in the 2 groups. The virologic response rates were similar in patients receiving and not receiving antiretroviral treatment at the time of treatment.

**Adverse Events**

There were no deaths or discontinuations observed in this study. Most adverse events were grade 1 in severity, with the most common being nasal congestion, myalgia, headache, and fatigue (Table 3). There were 4 grade 3 events, namely, decreased absolute neutrophil count, pneumonia, elevated aspartate aminotransferase level, and right upper quadrant pain. There was 1 grade 4 event (abnormal creatine phosphokinase level) in a participant who reported initiation of a vigorous exercise program, which resolved while the patient was still receiving study drugs. There was 1 significant adverse event reported in a smoker with a history of chronic bronchitis who was hospitalized with pneumonia in the winter. Symptoms resolved while the patient was receiving study drug, and the adverse event was determined to be unlikely related to the study drug.

**Changes in Renal Function**

At baseline, median serum creatinine levels were significantly different between patients not receiving antiretroviral treatment (0.81 mg/dL [to convert to μmol/L, multiply by 88.4]) and those receiving treatment (0.91 mg/dL) \( (P = .01) \). There were no significant changes in estimated serum creatinine levels or eGFRs over time (Table 4, eFigure 5 in Supplement 2). No participants were identified as having a treatment-emergent eGFR less than 50 mL/min or a decrease in eGFR (mL/min) greater than 25%.

### Table 3. Treatment Discontinuations, Adverse Events, and Hematologic Abnormalities

<table>
<thead>
<tr>
<th>Variable</th>
<th>Antiretroviral Therapy, No. (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No (n = 13)</td>
</tr>
<tr>
<td>Treatment discontinuation</td>
<td>0</td>
</tr>
<tr>
<td>Any adverse event</td>
<td>13 (100)</td>
</tr>
<tr>
<td>Common adverse event</td>
<td></td>
</tr>
<tr>
<td>Nasal congestion</td>
<td>2 (15)</td>
</tr>
<tr>
<td>Myalgia</td>
<td>5 (38)</td>
</tr>
<tr>
<td>Headache</td>
<td>1 (8)</td>
</tr>
<tr>
<td>Fatigue</td>
<td>3 (23)</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>2 (15)</td>
</tr>
<tr>
<td>Nausea</td>
<td>1 (8)</td>
</tr>
<tr>
<td>Constipation</td>
<td>2 (15)</td>
</tr>
<tr>
<td>Urinary tract infection</td>
<td>1 (8)</td>
</tr>
<tr>
<td>Serious adverse event</td>
<td></td>
</tr>
<tr>
<td>Pneumonia</td>
<td>1 (8)</td>
</tr>
<tr>
<td>Hematologic abnormality*</td>
<td></td>
</tr>
<tr>
<td>Increased aspartate aminotransferase (201-400 U/L)</td>
<td>0</td>
</tr>
<tr>
<td>Increased blood creatinine phosphokinase (56130 U/L)</td>
<td>0</td>
</tr>
<tr>
<td>Decreased neutrophil count (0.500-0.749 K/uL)</td>
<td>1 (8)</td>
</tr>
<tr>
<td>Elevated lipase (181-300 U/L)</td>
<td>0</td>
</tr>
</tbody>
</table>

* Percentage represents proportion of patients who had at least 1 laboratory value above the upper limit of normal.
One patient developed treatment-emergent hypophosphatemia (serum phosphorus level, 2.5 mg/dL [0.81 mmol/L]; grade 1) associated with a transient elevation in serum creatinine level, which resolved with treatment. This patient was receiving rilpivirine/tenofovir/emtricitabine and raltegravir. Two additional patients developed normoglycemic glycosuria that resolved with treatment.

### Changes in HIV Parameters

Eight participants receiving antiretroviral treatment who experienced an increase in HIV viral load (HIV-1 RNA ≥40 copies/mL, ≥1 log increase from nadir [eTable 3 in Supplement 2]) while in the study. All 8 participants achieved SVR12. One participant had a greater than 1 log increase in HIV viral load. This participant had missed 5 days of antiretrovirals (rilpivirine/tenofovir/emtricitabine + raltegravir) and had an HIV viral load of 594 copies/mL at week 4. He continued the same regimen. By the next visit (week 8), his HIV viral load was less than 20 copies/mL and he also achieved SVR12. Participants not receiving antiretroviral treatment who had HIV RNA levels greater than 50 copies/mL at baseline did not experience any significant increases in their HIV viral load over the course of therapy (eTable 4 in Supplement 2). There were no significant changes in CD4 cell counts or CD4 cell percentages with treatment for participants both receiving and not receiving antiretroviral treatment (eTable 5 in Supplement 2).

### Adherence

Adherence to ledipasvir and sofosbuvir, as measured by pill counts, was high over the course of treatment. Fifty percent of all participants had no missed doses (54% among participants not receiving antiretroviral treatment; 49% among participants receiving antiretroviral treatment). Fortyeight percent of patients missed 1 to 4 doses of study drug, for an adherence rate greater than 95%. Five patients missed 5 or more doses of study drug over the course of treatment. As determined by pill count at the end of study, the participant who experienced HCV viral relapse by week 4 after treatment completion reported no missed doses.

### Discussion

In this open-label, uncontrolled, nonrandomized trial, the combination of ledipasvir and sofosbuvir was associated with high rates of SVR in participants co-infected with HCV genotype 1 and HIV, similar to that observed in patients monoinfected with HCV genotype 1.14 These results show for the first time, to our knowledge, that an interferon- and ribavirin-free therapy is associated with high SVR rates in patients co-infected with HCV and HIV.

Traditionally, interferon-based therapies have resulted in lower rates of SVR among patients co-infected with HCV and HIV as compared with patients monoinfected with HCV.5,6 However, recent studies have shown that the addition of directly acting antiviral agents (telaprevir, boceprevir, simprevir, and sofosbuvir) has increased SVR in patients co-infected with HCV and HIV, reporting similar rates of SVR that were observed with patients monoinfected with HCV.4,24,25 Yet many of these studies used interferon, ribavirin, or both concomitantly with an exacerbation of adverse events in HIV-positive patients.4,8,24,25 Most recently, the once-daily, single-tablet regimen of ledipasvir and sofosbuvir, with or without ribavirin, has been shown to be an effective regimen to treat hepatitis C in HIV-negative individuals.24,37,26

The participants included in this study had many previously described poor prognostic factors, namely, African American race (84%), male sex (74%), IL28B non-CC geno-
Ledipasvir and Sofosbuvir for HCV and HIV


Author Affiliations:
Division of Infectious Diseases, Institute of Human Virology, University of Maryland, Baltimore (Osinusi, Nelson, Silk, Gross, Price, Sajadi, Taiwani, Kottillil); Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland (Osinusi, Townsend, Nelson, Meissner, Polis, Faucci, Kottillil); Gilead Sciences Inc, Foster City, California (Osinusi, Subramanian, Pang, McHutchison); Critical Care Medicine Department, NIH Clinical Center, National Institutes of Health, Bethesda, Maryland (Kohli, Seamon, Siddharthan, Sims, Masur); Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc (formerly SAIC-Frederick, Inc), Frederick National Laboratory for Cancer Research, Frederick, Maryland (Kohli, Silk, Gross, Price); Department of Microbiology and Immunology, Medical University of South Carolina College of Medicine, Charleston (Meissner); Institute of Biostatistics and Mathematical Modeling, Johann Wolfgang Goethe University, Frankfurt, Germany (Bon, Herrmann); Unity Health Care Inc, Washington, DC (Hogan, Teferi); Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland (Proschan); Family and Medical Counseling Services, Washington, DC (Jenkins); Department of Pathology, National Cancer Institute, Rockville, Maryland (Kleiner); Center for Interventional Oncology, Radiology and Imaging Sciences, NIH Clinical Center and National Cancer Institute, Bethesda, Maryland (Wood).

Author Contributions: Drs Osinusi and Kottillil had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Osinusi, Kohli, Nelson, Sajadi, Teferi, Wood, Subramanian, Pang, McHutchison, Polis, Masur, Kottillil.

Acquisition, analysis, or interpretation of data: Osinusi, Townsend, Kohli, Nelson, Seamon, Meissner, Bon, Silk, Gross, Price, Siddharthan, Sims, Herrmann, Hogan, Taiwani, Proschan, Jenkins, Kleiner, Wood, Subramanian, Fauci, Masur, Kottillil.

Drafting of the manuscript: Osinusi, Townsend, Bon, Gross, Price, Herrmann, Wood, Masur, Kottillil.

Critical revision of the manuscript for important intellectual content: Osinusi, Townsend, Kohli, Nelson, Seamon, Meissner, Bon, Silk, Sajadi, Siddharthan, Sims, Herrmann, Hogan, Teferi, Taiwani, Proschan, Jenkins, Kleiner, Wood, Subramanian, Pang, McHutchison, Polis, Fauci, Masur, Kottillil.

Statistical analysis: Osinusi, Townsend, Meissner, Bon, Herrmann, Proschan, Kottillil.

Obtained funding: Masur, Kottillil.

Administrative, technical, or material support: Townsend, Kohli, Nelson, Seamon, Meissner, Silk, Gross, Sajadi, Siddharthan, Sims, Teferi, Wood, Subramanian, Pang, McHutchison, Masur, Kottillil.

Study supervision: Osinusi, Kohli, Pang, McHutchison, Polis, Fauci, Masur, Kottillil.

Review and critique of the manuscript: All authors.

Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Ms Gross reported receiving study medication from Gilead for another study and holding stock in Merck and Pfizer. Dr Hogan reported serving as a speaker or consultant for Gilead and VIH and serving as a speaker for Merck, Bristol-Myers Squibb, Abbott, and Boehringer Ingelheim. Dr Teferi reported receiving grants and personal fees from Gilead. Dr Taiwani reported serving as a speaker for Gilead. No other disclosures are reported.

Funding/Support: The Regulatory Compliance and Human Participants Protection Branch of the National Institute of Allergy and Infectious Diseases (NAIID) served as the study sponsor. This project has been funded in whole or in part with federal funds from the National Cancer Institute, National Institutes of Health (NIH), under contract HHSN261200800001E. This research has been supported in part by the NIAID. The study was also supported in part by the German Research Foundation (DFG) by the clinical research unit KFO 129. The study was partially funded by a Collaborative Research and Development Agreement between NIH and Gilead Sciences.

Role of the Funder/Sponsors: Gilead Sciences provided the study drug. The Regulatory Compliance and Human Participants Protection...
Branch was involved in the review and approval of the study via the usual peer review process as well as the study management but had no role in the design of the study; data collection and analysis; interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Drs Osinusi, Subramanian, Pang, and McHughson, employees of Gilead Sciences Inc, participated in the writing of the manuscript.

Disclaimer: The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US government.

Previous Presentations: Presented in part at the 49th Annual Meeting of the European Association for the Study of Liver Diseases (EASL); The International Liver Congress; April 9-13, 2014; London, United Kingdom; and at the 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD); November 7-11, 2014; Boston, Massachusetts.

Additional Contributions: We would like to acknowledge the contributions of the following individuals: Katie Watkins, BS, Erin Rudzinski, BS, and Susan Vogel, RN, BSN (clinical monitoring support), Judith Starling, PharmD, William T. Symonds, PharmD, and Lori Gordon (pharmacy), Vanessa Ecard, BS, Jerome Pierson, PhD, John Tierney, BSN, BPM (regulatory support); William Ronnenberg, JD/MIP, MS, Richard Williams, PhD, and Mike Mowatt, PhD (technology transfer support), Marc Teitelbaum, MD, CPI (sponsor medical monitor), Mary Hall (protocol support), Cathy Rehm, Sarah Jones, David Wu, BS, Leighton Daigh, BS, and Jessica Joli, BS (laboratory support), Richard Kwan, PAC, Lisa L. Barnett, MD, PhD, Tim Jolley, RN, Gabbie Diaz, RN, Jose Chavez, MD, Stephen Abbott, MD, Colleen Kotb, NP, Angie Price, NP, Tess Petersen, BS, Jose Chavez, MD, and Sonora Mitchell (clinical support).

REFERENCES


